Pfizer focuses on animal health growth; Genzyme arthritis med gets Japanese OK;

 @FiercePharma: Roche's Avastin gets FDA reprieve--for now. Article | Follow @FiercePharma

> Pfizer is aiming for big growth in its animal health division as it seeks to replace sales lost on blockbuster drugs set to lose patent protection. Report

> Japanese regulators approved Genzyme's arthritis treatment Synvisc for marketing by the Japanese company Teijin Pharma. Report

> Pfizer spent $2.3 million lobbying Congress and federal agencies in the second quarter on healthcare reform and other health economic issues, down from $5.6 million year-over-year. Report

> Johnson & Johnson spent $1.2 million in the second quarter lobbying the federal government on patent reform and economic issues, down from $1.6 million year-over-year. Report

> The Generic Pharmaceutical Association spent about $463,000 in the second quarter as it lobbied numerous federal agencies on issues that included the recently passed healthcare overhaul law. Report

> A new blood-thinning drug moved closer to U.S. approval on Monday, leading a pack of stroke-fighting medicines vying to compete in an estimated $10 billion a year market. Report

> Boston Scientific plans to buy privately held Asthmatx, maker of a catheter-based treatment for severe asthma, for at least $193.5 million as it reshapes its portfolio to focus on faster-growth medical technologies. Report

> Eye drugmaker Bausch & Lomb said Monday it finished the acquisition of the drug Miochol-E from Swiss drugmaker Novartis. Report

Biotech News

@FierceBiotech: Novartis shuts down Protez, shelves $400M antibiotic program. Article  | Follow @FierceBiotech

 @JohnCFierce: AZ, BMS tout new batch of PhIII diabetes data for dapagliflozin. Article | Follow @JohnCFierce

> Vivus offers upbeat assessment of two-year Qnexa data. News

> Immatics banks $70M to fund pivotal cancer vax trial. Report

> Boehringer gets unanimous support for blockbuster stroke drug. Article

Biotech Research News

> Booming Chinese drug market inspires major R&D effort. Story

> Preclinical pain drug shows first-in-class potential. News

> Researchers build artificial ovary. Article

Manufacturing News

> FDA OKs studies with iBio/Fraunhofer plant-based vax. News

> Expert sees "questionable observations" in recent warnings. Story

> Congress clips smoking e-mails to Weldon invite. News

> FTC green-lights Rx-360 supplier audits. Article

> Traditional cures-maker Bohai ready for liftoff as China expands healthcare. News

> ISPE proposes supply chain security programs. Story

And Finally ... The global cost of dementia will likely exceed $604 billion this year, or 1 percent of the world's gross domestic product, a new report says. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.